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11. INTRODUCTION
1.1 Antibiotic resistance in bacteria
1.1.1. Epidemiology of resistance
Since the introduction of penicillin into the clinical practice in 1938 [1], the antibiotic 
era had undergone big change. It means that the originally effective antibiotics had become 
step by step ineffective against certain bacteria of clinically importance, which leads to 
therapeutic failures. This phenomenon can be due to several causes: first of all the very wide 
spread application of penicillin from the fourties which had followed to the appearance of 
the first penicillin resistant S. aureus strain [2]. On the other hand, the inappropriate 
application of further more effective antibiotics: e.g. unwarranted prescribing of antibiotics 
by physicians and too short-time taking of medicines by patients, can cause the selection of 
bacterial strain having more moderate sensitivity against the drugs [3, 4, 5]. The insufficient 
hygienic conditions in hospitals, particularly on intensive care units, had lead also to 
appearance and spread of poliresistant bacteria [6]. Finally the antibiotic resistance can be 
due to the marvellous adaptable ability of bacteria to the changed environment, which ability 
can be due to their very plastic genetic stock [7, 8].
1.1.2. Definition of drug resistance
After the introduction of antibiotics into chemotherapy resistant bacteria were rapidly 
appeared due to acquiring genes coding for some resistance mechanism. However not all 
bacteria are intrinsically sensitive to all antibiotics. This type of “resistance” is called 
intrinsic resistance or bacteria with this phenomenon are termed insensitive. This 
phenomenon is a natural property of a certain bacterial strain and is predictable in clinical 
situation [9,10,11]
However the so-called acquired resistance is occurred among bacteria which are originally 
sensitive to a certain antibiotic. Two types of acquired resistance can be mentionable: in the 
case of mutational resistance in a large population of bacterial cells a very few individual 
cells may spontaneously become resistant to one certain drug and the long-term 
administration of this drug can select the resistant cells. In transmissible resistance, genes 
conferring antibiotic resistance are transferred from a resistant strain to a sensitive one. 
Exponential transfer and spread of existing resistance genes through a previously sensitive
2bacterial population is a much efficient mechanism than is the development of resistance by 
spontaneous mutation, however the selective pressure by the presence of appropriate 
antibiotics is also needed to genes becoming widespread. The mechanisms of different gene 
transfers are discussed later [10,12,13]
1.1.3. The genetic of resistance
All the properties of a microbial cell are determined by the microbial genome, which 
comprises the three sources of genetic information in the cell: the chromosome, plasmids 
and bacteriophages.
1.1.3.1. The bacterial chromosome
Each bacterial cell has a single chromosome which is known to form a single closed circular 
DNA molecule. In Escherichia coli this single DNA comprises about 4 x 103 kb (kilobases), 
is about 1,4 mm in length and encode for 1000-3000 genes. The chromosome is coiled and 
looped into a compact bundle in the cytoplasm and is not separated from the cytoplasm by 
any form of nuclear membrane. Transcription of DNA and translation of RNA can therefore 
proceed simultaneously ensuring very rapid synthesis of proteins which serves rapid 
accommodation for bacteria to changed environment [10,14]
1.1.3.2. The bacterial plasmids
The bacterial chromosome carries all the genes necessary for the survival and replication of 
the bacterial cell under most circumstances. Most of the bacteria also carry additional 
molecules of DNA (2-200 kb) known as plasmids, which are separate from, and normally 
replicate independently of, the bacterial chromosome (Figure 1.). Plasmids carry genes 
which confer a wide range of properties that are not essential for the survival of the cell 
under normal circumstances but provide survival advantage in unusual or adverse 
conditions. Many different kinds of plasmids have been described depending on the 
properties what they determine: Col plasmids carry genes for bacteriocins, bacterial proteins 
which can destroy other bacteria [15,16]. Virulance plasmids encode genes for toxins, 
adhesins and other proteins that allow the bacteria to establish infection and cause disease. 
The metabolic plasmids carry genes for unique metabolic properties of some bacteria. For 
instance nitrogen fixation by Rhizobium, or the F’ lac plasmid in E. coli which encodes the 
lactose permease enzyme for metabolization of lactose [17,18,19,20]
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Figure 1. Plasmids as small circles of DNA 
(www. Universe-review, ca/110- 71-plasmid.jpg)
1.1.3.3. The spread of antibiotic resistance genes [21 ]
The antibiotic resistance genes could horizontally spread by transformation, transduction, 
conjugation and also by artificially recombinant DNA technology.
In the course of transformation DNA fragments from a dead degraded bacterium or 
from artificially dispatching bind to DNA binding proteins on the surface of the competent 
recipient bacterium. Nuclease enzymes cut the bound DNA into smaller fragments. One 
strand of DNA is destroyed, the other strand penetrate the recipient bacterium. This donor 
DNA fragment is the exchanged for a piece of DNA fragments deriving from recipient by 
means of Rec A proteins [22, 23],
Transduction is DNA transfer transmitted by bacteriophages. In the lytic phase the 
virulent phage injects its nucleic acid content into bacterium, the genes of bacteriophage are 
expressed using the energy and enzymes of host cell, the synthesised elements of virus 
assemble and the virions release from host cell which is solved by this process. However the 
so-called temperated phages also injects their nucleic acid into host bacterium, but do not 
induce lytic cycle, but the phage-DNA will be a part of bacterial genome by integration into 
bacterial chromosome or only circularise and works as a plasmid. This is the lysogenic 
phase. For certain stimulation e.g. shock, UV-light this prophage can be activated and the 
lytic cycle takes place. When integrated phage-DNA cut out of bacterial chromosome some 
host genes can be witheut and will be a part of phage genom and by a next phage infection 
these genes of non-phage origin can be horizontally transferred into a new host bacterial cell. 
In the lysogenic phase the new genes are expressed altering the property of host cell. [24, 25]
PV3
v
4Conjugation is transmission of genes from a living donor bacterium to a recipient 
bacterium by the means of plasmids. The donor property is possessed on an extra 
chromosomal elements, on the so-called F+ plasmid, coding only for the sex pilus (in gram­
negative bacteria). The sex pilus binds to the recipient, then a plasma bridge is formed and 
after breaking F+ plasmid at ori T locus, one strand of F+ plasmid gets through the plasma 
bridge to the recipient, the other strand remains in the donor. Each strand then makes a 
complementary (transfer replication) and the recipient becomes an F+ donor. There is 
possibility to transfer chromosomal genes from Hfr donor strains to recipients. The F+ 
plasmid becomes linear and integrates into the determined place of chromosome. The linear 
plasmid still works as an F+ factor, it breaks at the ori T locus, forms sex pilus and plasma 
bridge and because of the integration the plasmid-chromosome complex gets through the 
plasma bridge to the recipient. The bacterial connection usually breaks before the transfer of 
the entire chromosome is completed so the reminder of F+ plasmid seldom enters the 
recipient. As a result there is a transfer of some chromosomal DNA from donor to recipient. 
[26,27,28]
Other plasmids like resistance plasmids (R-plasmid) coding for multiple antibiotic resistance 
and sex pilus formation are able to get to the sensitive recipient by the same process and the 
recipient becomes multidrug resistant and F+ so will be able to transfer R-plasmids to other 
sensitive strains.
1.1.4. The mechanisms of antibiotic resistance
The antibiotic resistance involves severe mechanisms and the situation of genes 
coding for the certain resistance can be also very diverse. The resistance mechanisms are the 
further: enzymatic inactivation of antibiotics, enzymatic modification of antibiotics, 
alteration of drug targets, bypass mechanisms which are alternative ways of the original 
biochemical processes to be inhibited, changing of permeability and active efflux 
mechanisms [29]
1.1.4.1. Enzymatic inactivation of antibiotics
In the case of P-lactam antibiotics the bacterial P-lactamases can destroy the drug by 
creating an enzyme-drug complex, then the p-lactam-ring splits with the inactivation of
5molecule and regeneration of the enzyme. The Gram- negative bacteria show wide range of 
p-lactamases depending on the localization of genes, ability of induction, range of spectra. 
According to the Bush - Livermore classification the (<class C” -type enzymes (amp C) are 
the most general among Enterobacteriaceae, are coded mostly on the bacterial chromosome, 
plasmids and integrons, and strains producing of this enzyme at high level can cause serious 
nosocomial infections due to selection mechanisms [30,31,32]. The “class A”-type enzymes 
(KI, KOXY) are produced mostly by Klebsiella spp, coded also on the bacterial 
chromosome and their overproduction causes resistance of high level to P-lactam antibiotics 
except for carbapenems and ceftazidime, “class B”-type enzymes (L-l, L-2) are metalo-p- 
lactamases, coded chromosomally and cause resistance to each p-lactam antibiotics 
including carbapenems in non-fermentative Gram- negative rods [33,34,35]. The so-called 
extended-spectra-p-lactamases (ESBL) are coded on plasmid, the TEM-1,-2, SHV-1, OXA- 
1 enzymes belong to this group. Among p-lactam antibiotics only carbapenems and 
cefamycins are effective on bacteria producing these enzymes. Since the resistance genes are 
coded on plasmid, these bacteria - mostly Klebsiella spp.- can easily transfer multiple 
antibiotic resistance to other bacterial strains via the process of conjugation causing 
dangerous nosocomial epidemic [36,37,38].
Macrolid antibiotics can be also inactivated by specific enzymes coded usually on plasmids.
1.1.4.2. Enzymatic modification of antibiotics
Amynoglycosides are neutralized by enzymes e.g. acetyl-transferaze, 
phosphotransferaze and nucleotidil-transferaze by connecting the certain groups into the 
molecules which become ineffective [39,40]. These enzymes are coded chromosomally or 
on plasmids. The chloramphenicol can be modified by chloramphenicol-acetyl-transferaze 
(CAT) [41,42].
1.1.4.3. Alteration of drug target
In cell wall synthesis the bacterial penicillin binding proteins (PBP) play a major 
role. During synthesis they bind the cell wall precursor, but the P-lactam antibiotics as well 
due to a structural similarity. In the last case the mechanism of cell wall synthesis destroys 
and the bacterium solves. However the structure of PBPs change without losing the ability to 
act normally at cell wall synthesis, but the antibiotics cannot bind PBP so P-lactams will be 
ineffective. Genes coding for the changed PBPs are usually derived from another species and
6due to transformation and later recombination these genes have so-called mosaic-structure 
[29,43,44]
In amynoglycosid resistance the bacterial 30 S ribosome alters as a target of antibiotic and 
in macrolid resistance the 50 S ribosomal subunit modifies with alteration of its rRNA base 
sequence. In tetracycline resistance the ribosome changes also by producing a protein which 
protects it from before antibiotic [45,46,47].
In the resistance mechanisms of glycopeptides the end of a protein involving in cell wall 
synthesis, as a structure-terminal-pentapeptid, alters from D-alanil-D-Ala to D-alanil-D- 
laktate which cannot be bound by glycopeptides, but it still works normally in synthesis. 
Genes coding for this kind of resistance mechanisms are often transferred from glycopeptide 
resistant Enterococci to MRSA (methicillin-resistance S. aureus) producing the so-called 
VRSA (vancomycin-resistant S. aureus) which bacterium is a threatening participant of 
bacterial infections [48,49,50].
1.1.4.4. Bypass mechanisms
When a biochemical process to be originally inhibited by antibiotics goes through in 
an alternative way, antibiotics won’t be able to influence it. It happens in the case of classical 
methicillin resistance of S. aureus which create an extra PBP, so-called PBP2a, which 
cannot be bound by any P-lactam. The MRSA strains are resistant to each P-lactam 
antibiotics and bear cross-resistance to some other antibiotic classes. Extra PBP 5 is 
produced in E.faecium as well meaning its ampicillin-resistance [49,51]. In sumetrolim and 
in trimethoprim resistance two bacterial biochemical intermediate product to be inhibited by 
antibiotics are overproduced, the PABA (para-amino-bensoe-acid) and DHFR 
(dihydrofolate-reductase) respectively. Genes coding for this resistance usually are localized 
on some mobile genetic elements e.g. plasmids, transpozones [29].
1.1.4.5. Changing of permeability
In Gram-negative bacteria the outer membrane contains the so-called protein porin- 
channels which ensure the enter of antibiotics and other unrelated compounds into the cell. 
Due to mutations decreasing the number of porins or changing the structure of porins follow 
to the increasing MIC values and/or resistance of beta-lactam antibiotics particularly of 
carbapenems. This happens in the case of isolated carbapenem-resistance of 
Enterobacteriaceae or isolated imipenem-resistance of P. aeruginosa which preserves 
sensitivity to meropenem [29,52,53,54].
71.1.4.6. Active efflux
The drug efflux can be realised through the working of bacterial drug transporters. 
Some transporters, such as the tetracycline efflux proteins (Tet), are dedicated systems which 
mediate the extrusion of only a given drug or class of drugs [55,56]. In contrast to these 
specific drug transporters, the so-called multidrug transporters can handle a wide variety of 
structurally unrelated compounds and can be divided into two major classes. Secondary 
multidrug transporters utilize the transmembrane electrochemical gradient of protons or 
sodium ions to drive the extrusion of drugs from the cell, ATP-binding cassette (ABC-type) 
multidrug transporters use the free energy of ATP hydrolysis to pump drugs out of the cell 
[55,57,58, 59],
1.1.4.6.1. Secondary multidrug transporters
These transporters mediate the extrusion of toxic compounds from the cells in a 
coupled exchange with protons. On the basis of size and similarities in the primary and 
secondary structure, they can be divided into four distinct families of transport proteins.
1.1.4.6.1.1. major facilitator superfamily (MFS)
It consists of membrane transport proteins which can be divided into two separate clusters 
with either 12 or 14 transmembrane segments (TMS) [60] (Figure 2).
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Fig 2. Structural model for the 12-TMS multidrug transporters of the MFS. Conserved sequences are shaded.
In the 12 TMS class the S. aureus Nor A (norfloxacin) protein was first discovered in 
quinolone- and methicillin-resistant clinical isolate [61,62] and two proteins, Bmr and Bit of 
B. subtilis can be mentionable [63,64].
The 14 TMS class of MFS comprises among others the QuacA and QacB (quaternary 
ammonium compounds) proteins which play a major role in the resistance to antiseptic and
8disinfectant compounds among multidrug-resistant S. aureus by pumping out cationic dyes/ 
membrane-permeable organic cations and quaternary ammonium disinfectants [65,66]
1.1.4.6.1.2.small multidrug resistance (SMR) family 
The smallest secondary drug efflux proteins known consist of tightly packed four-helix 
antiparallel bundle and may function as homooligomeric complexes due to the small size
[67].
The firs gene (qacD) encoding a transporter protein of the SMR was detected on both 
conjugative and nonconjugative plasmids from clinical isolates of S. aureus [68,69,70]. 
Among gram-negative bacteria among others the E. coli multidrug transporter, EmrE 
(MvrC) has been identified. It is situated in the inner membrane layer and the drugs appear 
to be exported into the periplasmic space. Overproduction of the protein makes E. coli 
slightly more resistant to tetracycline, erythromycin and sulfadiazine. The pumps of Smr 
type, however, are not known to make significant contributions to clinically relevant 
resistance among gram-negative bacteria [71,72].
1.1.4.6.1.3. multidrug and toxic compound extrusion (MATE) family 
It contain 12 putative TMS similarly to MFS but do not have sequence similarity with any 
member of MFS. NorM in V. parahaemolyticus and YdhE in E. coli belong to this group 
mediating resistance to dyes, hydrophilic fluoroquinilones and aminoglycosides. The third 
distinct cluster hypothetically comprises multidrug efflux proteins from H. influanzae 
[73,74].
In gram-negative bacteria the former transporters situated in the inner layer of plasma 
membrane cannot be effective enough since the lipophilic compounds can spontaneously 
diffuse back from the periplasmic space into the cytoplasm. More complex systems were 
needed for clinically relevant drug resistance for gram-negative bacteria.
LL4.6.1.4. The Resistance Nodulation Cell Division family (RND)
Multidrug transporters belonging to the RND family are located in the cytoplasmic 
membrane; interact with a periplasmic membrane fusion protein (MFP) and an outer 
membrane channel protein (Figure 3.) to allow drug transport across both the inner and the 
outer membrane of gram-negative bacteria. Because these pump systems can excrete drug 
molecules directly into the medium, they can produce significant resistance levels [75,76].
91.1.4.6.1.4.1. Structure of RND-type transporters
The secondary structure of RND-type transporters /efflux proteins consist of 12 TMS 
a-helix with two large loops between TMS1 and 2 and TMS 7 and 8 (Figure 3.) [77]. Like 
any other secondary transporters it also uses proton motive forces (PMF) for the active 
efflux of compounds.
Fig. 3. Structural model for the multidrug transporters of the RND family. The shaded conserved motifs on 
Figure 2,3 are charged amino acid residues in TMS which is energetically unfavourable suggesting important 
structural and functional role in the transporters. Motif A may be involved in reversible conformational change 
required for the opening / closing of the transport channel. Motif B is responsible for proton transfer. Motif C 
dictates the direction of transport, that’s why isn’t found in symporters of MFS.
1.1.4.6.1.4.2. Structure and role of AcrAB-TolC efflux pump
One of the main representatives of this type of pumps and one of the main participant 
of this thesis is the so-called AcrAB-TolC efflux pump system in E.coli (Figure 4.). Acr B is 
the RND-type transporter, AcrA is the periplasmic membrane fusion linker protein (MFP), 
which links the inner membrane (containing the AcrB transporter) and the outer membrane 
channel protein, TolC, together. This is reinforced by the finding that the member of MFP 
have some homology with a paramyxovirus membrane fusion proteins [75,72],
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Figure 4. The structure of AcrB-TolC efflux pump system 
(www. indigói, biop. ox.ac. uMoredana/acrb. html)
It is well known that activator proteins are produced at a higher level in response to 
the presence of antibiotics, superoxid radicals and these regulator proteins are known to 
increase the efflux of several drugs [78,79,80], In addition to the increased transcription of 
the acrAB operon containing the genes coding for proteins of AcrAB pump, the activator 
proteins down-regulate the synthesis of the major porin OmpF. The decreased outer 
membrane permeability thus synergistically enhances the effect of an increased production 
of the efflux machinery [79],
1.1.4.6.1.4.3. Substrates ofAcrAB-TolC efflux pump, mechanism of drug efflux
AcrAB system pumps out an extraordinary wide variety of antibiotics, 
chemotherapeutic agents, detergents and dyes. Many of the substrate carries net negative 
charge, but there are also compounds with positive charges, such as cationic dyes and 
erythromycin. The common characteristics among substrates can be glimpsed by examining 
drugs that are not exported by this system. There is no evidence for the efflux of the very 
hydrophilic aminoglycosides [81,82], It is evidence that AcrAB system can produce 
significant resistance to large hydrophobic agents e.g. erythromycin which was studied in the 
experiments involved in this thesis as well [83,84], Most of the natural antibiotics belong to 
this class and their range has traditionally been considered to be limited to gram-positive 
bacteria. The intrinsic “gram-negative-resistance” is often caused by the efflux pumps of the 
whole RND family [71,85] and efflux work in synergy with the outer membrane barrier [79], 
The multidrug transporters transport their hydrophobic substrate from the lipid 
bilayer rather than from cytoplasmic aqueous phase. The only requirement for AcrAB pump 
is that the hydrophobic substrate becomes inserted into the lipid bilayer of the membrane. It 
is proposed that the substrates are captured from within the bilayer [75,86,87],
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1.1.4.6.1.4.4. Homologues ofAcrAB-TolC efflux pump
The AcrAB and its homologues are apparently widespread among gram-negative 
bacteria. Among Pseudomonas aeeruginosa strains among others the MexAB-OprM, 
MecCD-OprJ and MexEF-OprN [88,89,90]. Further examples include MtrCDE in Neisseria 
gonorrhoeae [91] and a homolog found in Haemophilus influenzae [92]. A homolog of the 
outer membrane channel TolC was also found in Burkholderia cepacia [93].
1.1.4.6.1.5. The normal physiological function of multidrug transporters 
The drug-efflux pumps are certainly not a recent product of the antibiotic age. The 
normal physiological function of multidrug transporters with special regard to the RND-type 
pumps is to play a role in natural defence mechanisms of bacteria against toxic compounds 
that exist in the environment. First lots of gram-negative bacteria live in a habitat with high 
concentration of lipophilic inhibitors, e.g., E. coli is faced with bile salts and fatty acids in 
the intestinal tract. AcrAB was shown to play role in the efflux of bile salts allowing E. coli 
to survive in such environment [94]. Similarly N. gonorrhoeae strains isolated from the 
rectum frequently overproduce the MtrCDE pump [91] which allows survival in an 
environment full of lipophilic inhibitors [95]. Second, the extremely wide substrate 
specificity of these pumps will be best suited for this defensive role, as the bacterium cannot 
predict the nature of the inhibitor it will face. Third, the AcrAB pump appears to be 
regulated more by global stress signals rather than by presence of specific substrates [80]. 
Fourth endogenous substrates have not been found for any of these pumps [71].
Genes determining multidrug resistant efflux pumps are mostly situated on bacterial 
chromosome but there are any reasons to fear that these genes can become a part of R 
plasmids, because divalent cation efflux pumps that contain the three components of the 
RND-family [75,76] are already known on plasmids [96], thus, R plasmids may indeed 
acquire the genes for multidrug efflux pumps in the future.
1.1.4.6.2. ATP-dependent multidrug transporters
Although most bacterial multidrug transporters utilize the PMF (proton motive 
forces) (or sodium) for the extrusion of cytotoxic compounds, some drug efflux systems are 
driven by free energy of ATP hydrolysis. All ATP-dependent drug efflux proteins known to 
date are members of the ABC (ATP-binding cassette) superfamily.
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1.1.4.6.2.1. Structure of ABC transpsorters
ABC transporters require four distinct domains: two highly hydrophobic (N-terminal) 
membrane domains, which usually consist of six putative transmembrane a-helices each, 
and two hydrophilic (C-terminal) nucleotide binding domains (NBDs), containing the 
Walker A and B motifs [97] and the ABC signature [98] (Figure 5.). The individual domains 
can be expressed as separate proteins or may be fused into multidomain polypeptides 
[98,99],
?*ccccdS
Figure 5. Structural model for multidrug transporters of the ABC superfamily with Walker A 
and B motifs and with ABC signature sequence which are shaded. In view of the general 
four-domain organization, it may function as a homodimer.
1.1.4.6.2.2. Homologues among ABC transporters: bacterial LmrA, haemolysin 
transporter and human P-glycoprotein
Most bacterial ABC drug transporters mediate the export of specific antibiotics 
[100,101,102], The firs true bacterial ABC multi drug transporter was found in Lactococcus 
lactis [103] and the gene encoding this transporter, designated ImrA. LmrA protein is 
homologous to each of the two halves of the human multidrug transorter P-glycoprotein (P- 
gp) (see below) [ 104] and these two transporters are functionally interchangeable, indicating, 
that this type of multidrug transporter is conserved from bacteria to humans [105]: genome 
sequencing revealed the presence of putative LmrA homologues in E. coli, B. subtilis, and 
the pathogens Helicobacter pylori, Mycobacterium genitalium, H. influenzae and S. aureus
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[106]. It is common, that TMS 5,6,11 and 12, and the loop between TMS 2 and 3, and TMS 
11 and 12 are most important in drug binding and/or transport [107,108,109]. Moreover 
LmrA and P-gp includes parts of TMS 5 and 6 and the loop between TMS 2 and 3 [104], 
indicating that these particular regions may be important for substrate binding in both human 
and bacterial ABC-type multidrug transporters. The HlyB transporter of E. coli is involved 
in transport of bacterial haemolysin and has also a structural similarity with the human P-gp. 
Both have channel-forming functions that act like a flippase (an enzyme which translocate 
lipids in membranes between the two bilayers). The extent of the protein sequence homology 
between P-gp and HlyB transporters suggests that these two proteins share a common 
function in the plasma membrane, exporting molecules from the cells [110]. Moreover drugs 
of similar chemical structure e.g. certain type of phenotiazines can inhibit both transporters 
indicating their structural and functional similarity [111].
1.2. Resistance mechanisms in tumour cells
In cancer therapy the tumour cells may demonstrate single agent resistance or 
resistance to a single class of anti-cancer drugs with the same mechanism of action. This can 
be overcome by addition of different classes of drugs to a chemotherapy regimen. However 
there may be cells which are broadly resistant to many chemically diverse anti-cancer drugs 
with different mechanisms of action. The latter phenomenon is the multidrug resistance 
(MDR) and is a more urgent problem than former one [112]. Several different resistance 
mechanisms cause MDR e.g. interference with programmed cell death following treatment 
with cytostatics by inactivation of p53 [113], resistance-related abnormalities of enzyme 
topoisomerase II [114,115], overexpression of genes involved in the glutathione S-transfer 
system [116,117], and expression of energy-dependent pump systems which either exclude 
or extrude anti-cancer agents from the cells.
1.2.1. ABC transporters in tumour cells
One of the largest protein classes known, the ABC (ATP-binding cassettes) 
transporters (Figure 5.) using energy deriving from ATP hydrolysis for pumping the drugs 
out of the cells, are involved in most cases of this mechanisms [118,119,120]. Three major 
groups of ABC transporters may play a role in tumour’s intrinsic and/or acquired resistance:
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1.2.1.1. The multidrug resistance-associated protein (MRP or ABCB1) group
It involves seven member e.g. MRP 1-7 (or ABCC1-6 and ABCC10) and consists of 
two homologous halves each containing six transmembrane regions and one ATP binding / 
utilization site (see below structure of p-gp) [112,121]. MRPs are (multispecific) organic 
anion transporters, which can transport water-soluble negatively charged anionic drugs and 
hydrophobic uncharged molecules as well. Transport of neutral drugs is carried out by their 
conjugation to glutathione, glucuronate or sulphate. MRP4 and MRP5 broaden the spectrum 
of drug resistance to nucleotide analogue drugs [121,122]
1.2.1.2. The breast cancer resistance protein (BCRP) (also known as MXR, ABCP,
ABCG2)
This is a novel member of ABC transporters. The termination is due to the fact that it 
was recently discovered at first time in MCF-7/AdrVp human breast carcinoma cell line. The 
protein consists of 655 amino acids, altogether is about 72 kDa and maps to chromosome 
4q22. BCRP belongs to the ABC G subfamily and is structurally a so-called half-transporter 
[120,123]. It forms a dimer to produce an active transport complex. In contrast to MRP, 
BCRP preferentially extrude large hydrophobic, positively charged molecules [122,123,124] 
1.2.1.3. P-glycoprotein
The third major member of ABC transporters is the MDR1 or p-glycoprotein. A 
protein, which is one of the main causes of clinical MDR in tumour cells and which is the 
most studied transporter protein in MDR reversing experiments. /Details see below/
1.2.2. Lung resistance-related protein (LRP!
The further protein is not a member of ABC transporters but is also a transport- 
associated protein termed the lung resistance-related protein (LRP). LRP was identified as 
the major vault protein (MVP), the main component of multimeric vault particles. With the 
recent identification of the two minor vault proteins as telomerase-associated protein (TEP1) 
and vault-poly (ADP-ribose) polymerase (VPARP), the composition of vaults is almost 
unravelled [125]. Vaults are novel cellular organelles broadly distributed and highly 
conserved among diverse eukaryotic cells, suggesting they play a fundamental role in cell 
life. Since the localization of vaults is in the nuclear pore complexes, nucleocytoplasmic 
transport of several diverse drugs by vaults may be supported causing multidrug resistance. 
There is direct evidence for a casual relationship between LRP/MVP expression and drug 
resistance. LRP is widely distributed in clinical cancer specimens, but the frequency of LRP
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expression inversely correlates with the known chemosensitivity, so its expression at 
diagnosis predicts poor prognosis. [125,126]
1.2.3. The structure and role of human P-glvcoprotein / MDR1
The 170 kDa transporter protein (p-gp 170) may be the major factor of cancer cells’ 
multidrug resistance. It belongs to the superfamily of ABC transporters (see above) (Figure 
5.). The mctrl gene, a so-called SOS gene, involved in p-gp 170 protein production is 
localized in human chromosome 7 band p 21,0 - 21,1 [127], P-gp is 1280 amino acids in 
length. The primary amino acid sequence predicts a protein with 12 transmembrane domains 
in two homologous halves, each containing six transmembrane regions with 43 % amino 
acid-sequence homology between the amino- and carboxy-terminal halves, and two large 
intracytoplasmic loops encoding an ATP-binding and utilization sites (also called nucleotide 
binding sites / NMSs) [128,129,130] (Figure 6.).
Figure 6.. The structure of P- 
glycoprotein 170 molecule with 
two nucleotide binding domain 
(NB1 and NB2)
(www. uoguelph. ca/~fsharom/rese 
arch/images/trp topology on wh
itegif)
1.2.3.1. Substrates and operation of human P-glycoprotein
The mdr-1-encoded P-glycoprotein pump recognizes and transports out of the cells 
many different substrates, including most natural product anti-cancer drugs such as 
doxorubicin, daunorubicin, vinblastine, vincristine, actinomycin D, paclitaxel, teniposide 
and etoposide which only share the properties of being hydrophobic amphipathic molecules 
which are not negatively charged (opposite to MRP) [131], However it may thus able to 
recognize negatively charged hydrophilic compounds if they enter the cell by passive 
diffusion and become accessible to the pump from the membrane environment [132,133].
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Consideration of the extremely broad range of substrates, two possible models for the 
transport action exist: first, the “ altered partitioning” model envisions tbat overexpression of 
p-glycoprotein leads to an alteration of the cell’s electrical membrane potential and / or an 
elevated intracellular pH. These perturbations then either directly or indirectly alter the 
partitioning and intracellular drug accumulation and the electrochemical and / or H+ gradient 
acts to drive the movement of charged drugs across the membrane. In this model the p-gp 
itself is not a drug transporter, but has an indirect role in modifying the intracellular 
environment [134,135]. Second, in the “pump model”, the energy of ATP hydrolysis by p- 
glycoprotein is utilized for the removal of drugs from cell membranes and cytoplasm 
analogous to the ion-translocating pump. The pump recognizes substrates directly through a 
complex substrate recognition region. In this model the p-gp does work as a drug transporter 
(efflux pump) [136,137,138]
The majority of the published data strongly favours the second model, as evidence for a 
direct interaction of many of the substrates with the transporter has been obtained including 
drug binding sites on p-gp, drug-stimulated ATPase activity in direct proportion to the 
ability of p-gp to transport these drugs. Arguments for the “altered partitioning” model are 
supposed by the finding of increased cytoplasmic pH and altered membrane potential in 
some cells that express p-glycoprotein [134,139]. However evidences argue that these 
electrochemical gradients are not in themselves sufficient to account for the high level of 
drug resistance seen in many multidrug resistance cells expressing p-glycoprotein [112]. 
There seems no doubt that substrates for transport by p-gp interact directly with the 
transporter - probably in the region of transmembrane segments 5,6 and 11,12 [140,141]. It 
has proposed that p-glycoprotein is a “hydrophobic vacuum cleaner” or a “flippase” 
[142,143] as the anticancer drugs enter the plasma membrane and the drugs with a 
hydrophobic and a positively charged domain demonstrate diffusion into and across the 
plasma membrane, where encounter the multidrug transporter by lateral diffusion. The 
transporter uses energy transduced from two essential ATP binding sites to pump the drug 
out of the membrane [144]. The p-glycoprotein itself catalyzes substrate-stimulated ATP 
hydrolysis at a rate similar to other ion-translocating ATPases [130], and although both 
NBSs (nucleotide binding sites) of p-gp bind ATP, and the interaction of both sites is 
required for ATP hydrolysis, only one site at a given time acts as a catalytic site and the 
confirmation of this site prevents the other one from hydrolyzing ATP [145,146].
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1.2.3.2. Post-translational modifications of human P-glycoprotein
P-gp is post-trsanslationally modified by glycolization and phosphorylation. 
Experiments show that glycosilation of p-gp is not required for its multidrug transport 
function, however it has been suggested that N-glycosilation may contribute to the correct 
folding, proper routing and stabilization of the molecule [147,148,149].
P-gp has five sites which can be phosphorylated on serine and threonine residues by protein 
kinase (PK) C, PKA or another p-gp-specific kinase at positions situated in the linker region 
of the molecule [150,151, 152]. Evidences are supported that phorbol esters which activate 
PKC, might be attributable only to the stimulation of transcription of the p-glycoprotein gene 
and not to the increasing of drug resistance [153,154].
1.2.3.3. Normal physiological  function of human P-glycoprotein
The P-glycoprotein is expressing not only in cancer cells, however a plenty of human 
tissues express this protein with normal physiological function. Expression was found on 
luminal surfaces of epithelial cells of the kidney proximal tubules, small and large intestine, 
and biliary hepatocytes, suggesting a normal function for the excretion of endogenous and 
exogenous hydrophobic, amphipathic toxins. Expression on capillary endothelial cells of the 
brain and testis and in the placenta suggested a ‘barrier’ function to keep toxic materials out 
of the brain, gonads and foetus. High level expression of P-gp in the adrenal cortex, 
pancreatic ductules and in steroid-producing endometrial glands in the pregnant uterus have 
suggested a role in transporting hormones such as aldosterone, dexamethasone, cortisol and 
corticosterone [155] and in the handling of steroids-perhaps providing a ‘protective’ function 
for the plasma membranes of steroid producing cells. Lower expression of P-gp was found in 
bone marrow stem cells [155,156,157]. Several studies have demonstrated increases in RNA 
levels for P-gp after partial hepatectomy, treatment with chemotherapeutic drugs and 
cytotoxic stress such as heat shock [158,159].
1.2.3.4. Presence of P-glycoprotein in malignant tumours
The process of malignant transformation in cancer derived from tissues that do not 
normally express P-gp can activate expression of the mdrl gene [160]. Increased expression 
of the mdrl gene is commonly seen in tumours treated with chemotherapy that have relapsed 
during the course of, or after chemotherapy like in the cases of breast cancer, ovarian cancer, 
lymphoma, leukaemia, neuroblastoma, pheochromocytoma, rhabdomyosarcoma and 
multiple myeloma. In these cases it is presumed that small numbers of mdr 1-expressing cells 
were present when therapy was initiated and that this population survived chemotherapy and
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caused the relapse. But a direct effect of chemotherapy to induce mdrl gene expression is 
also possible [161].
1.3. Possibilities for overcoming drug resistance in bacteria and tumour cells
The main aim of this work —after the introduction of the different type of resistance in 
bacteria and tumours - is to demonstrate some practical solutions to overcome resistant in 
bacteria and tumour cells as well. Theoretically decreasing the resistance can be achieved by 
different ways: in bacteria eliminating the extrachromosomal genetic elements (e.g. 
plasmids), inhibiting their intercellular transfer in the population and enhancing the uptake of 
antibiotics, exerting direct effects on drug accumulation of microorganisms and cancer cells 
as well by either direct inhibition of their efflux transporter proteins.
At the Department of Medical Microbiology at University of Szeged intensive experiments 
have been carried out since the seventies in the field of reversing drug resistance. First of all 
some phenotiazines, e.g. chlorpromazine, levopromazine and promethazine were shown to 
have bacteriostatic and bactericide effect, and the chlorpromazine was effective in 
eliminating of R factor indicating having some resistance reversal effect [162]. Later further 
more psychotropic drugs were shown to have antiplasmid effect, since the F’lac plasmid of 
E. coli was successfully eliminated [163] and the mechanism of plasmid curing by surface 
action of the drugs was suggested as an alternative to direct intercalation of the drugs into 
plasmid DNA [164]. Later it was found that the guanine-cytosine rich regions of plasmid- 
DNA is the target in the antiplasmid effect of phenotiazines [165]. Alterations in the 
bacterial membrane such as discontinuities, phase separation or rarely extensive lytic 
alterations caused by some phenotiazines, imipramine were observed during elimination 
experiments and the drugs were proved to bind to two different receptor sites (strong and 
weak) simultaneously on the plasmid replication site [166,167]. The tricyclic configuration 
of the psychotropic drugs, which were tested for stereospecific binding to bacterial receptors, 
was found to be more important than its side chain orientation and similarity is believed 
between bacterial and neural receptor sites. The stereochemical configuration of the curing 
agents does influence the complex process of plasmid elimination [168,169]. The tricyclic 
compounds having antiplasmid effect were divide into three groups according to the 
numbers (0,1 or 2) of heteroatom in their ring system serving a guideline for drug design in 
the future to develop related potent substances with less side-effect [170].
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However the elimination of antibiotic resistance-encoded plasmids from all individual cells 
of the population is never complete. Its medical significance could be that elimination 
method may provide a technique to isolate plasmid-free bacteria for biotechnology without 
any risk of mutations.
This thesis introduces experiments by which the antibiotic resistance could be reduced in all 
the cell of the population by the chemical inhibition of the drug efflux pumps in bacteria and 
tumour cells as well resulting the increased accumulation of antibiotics and cytostatics in 
bacteria and cancer cells respectively.
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2. AIMS OF THE THESIS
For the rapidly increasing antibiotic resistance urging solutions are needed: either by 
the introduction of new antibiotics, or by combinations of old antibiotics with resistance 
modifier agents. In earlier works the reversal of antibiotic resistance meant the elimination of 
plasmids which confer genes for resistance. Since elimination never occurs in the whole 
population a more effective mechanism was found for increasing the accumulation of drugs 
in each cell of the population, namely the inhibition of proton- (in bacteria) and ABC- (in 
tumours) pumps -extruding wide range of structurally unrelated compounds or xenobiotics 
out of the bacteria and tumour cells- by different chemical agents.
1. The antibacterial effect of the resistance modifiers such as trifluoro-methylketones, as 
known proton pump inhibitors (e.g. Omeprasol), other known resistance modifiers eg. 
verapamil, a phenotiazine e.g. promethazine, were determined on E. coli AG100 (operating 
with proton pump) resistant strain and 100A (proton pump defective) sensitive strain.
2. The most potent trifluoro-methylketones were chosen and examined for interaction in 
antibacterial effect with promethazine and verapamil in checkerboard microplate method on 
E. coli AG100 and AG100A.
3. A clinically important model was constructed, when E. coli AG100 and AG100A 
were transformed with pBR322 plasmid. These bacteria were considered as clinical model of 
resistant bacteria. The elimination of pBR322 plasmid by promethazine from the two E. coli 
strains can provide clinical relevance.
4. The most potent trifluoro-methylketone, l-(2-benzoxazolyl)-3,3,3-trifluoro-2- 
propanone (TF18), was examined in checkerboard method with some representatives of 
antibiotics (tetracycline, ampicillin, erythromycin) on E. coli AG 100 and AG100A for 
inhibitory effect.
5. Since l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone (TF18) was found to be a 
potent proton pump inhibitor and resistance modifier, other known proton pump inhibitor 
(Omeprasol), and l-(2-benzoxazolyl)-2-propanone (TF51) -a structurally close derivative of 
TF18- were studied in combination with erythromycin on E. coli AG100 and AG100A .
6. Known resistance modifier (promethazine, verapamil) were applied in combination 
with erythromycin and ampicillin on both E. coli strains.
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As direct evidence for interaction of trifluoro-methylketones with proton motive 
forces the antimotility action of the compounds was examined on the bacterial motion 
treating P. vulgaris cells.
The correlation between the chemical structure of trifluoro-methylketones and their 
antibacterial, antimotility and proton pump inhibitory effects were studied.
7.
8.
9. In cancer cells, for the possible multidrug resistance reversal effect, the drug 
accumulation was tested by the Rhodamine-123 extrusion assay. For these experiments
• acridine derivatives: aza mono, bi- and tricyclic 
compounds
• benzonaphthyridine-5-one derivatives were studied
10. The relationship between the chemical structure of effective agents and the biological 
effect was evaluated with particular respect to the type of aromatic moiety, and the structure 
of the side chains (substituents and size)
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3. MATERIALS
3.1. Culture media for bacteria
MTY / tryptone-yeast extract media /: liquid media was used for the cultivation of E. coli 
AG 100, AG100A and P. vulgaris bacterial strains. /171/
MTY agar: was used for the determination of live cell counts of E. coli AG 100, AG100A 
and P. vulgaris culture. It was used for the maintenance of the mentioned bacterial strains. 
YTB / Yeast extract -Tryptone Broth /: liquid media was used for the cultivation of E. coli 
AG100, AG100A strains to be transformed with pBR322 plasmid and was used for the 
dilution of bacteria during transformation procedure.
YTB agar /supplemented with tetracycline and ampicillin / was used for the plating, 
cultivation and selection of E. coli AG100 pBR322 and AG100A pBR322 strains.
3.2. Media for cell line cultivation
McCoy’s 5A medium modified (GIBCO BRL) /172,173,174/
PAR: Streptomycin, Nystatin, 200 mM L-glutamine, 10 % heat inactivated horse serum 
MDR: Streptomycin, Nystatin, 200 mM L-glutamine, 10 % heat inactivated horse serum
3.3. Stock solution for preparation of competent cells
Calcium chloride (CaCfe) 1.0 M, Magnesium chloride (MgCh) 1.0 M, potassium chloride 
(KCl)l.OM
3.4. Dye
3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma)
3.5. Strains and cell lines
3.5.1. Bacterial strains
Laboratory strains: E. coli AG 100, E. coli AG 100A were constructed and kindly provided 
by Professor Nikaido (University of California, USA), E. coli AG 100 pBR322 and E. coli 
AG 100A pBR322: the former two strains transformed with pBR322 plasmid respectively
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Clinical isolate: P. vulgaris (derived from Institute of Clinical Microbiology, University of 
Szeged),
3.5.2. Tumour cell lines
(provided by Professor Adóiján Aszalós, FDA, Washington, USA)
L5178Y mouse T cell lymphoma cell line (PAR)
L5178 mouse T cell lymphoma MDR 1 / A retrovirus transfected cell line (MDR)
3.6. Compounds studied
3.6.1. Ca channel inhibitors
Promethazine (Pipolphen®) (EGIS Pharmaceutical Company, Budapest, Hungary), 
verapamil (Verapamil®) (Chinoin, Budapest, Hungary)
3.6.2. Proton pump inhibitor
Omeprazol (AstraZeneca)
3.6.3. Antibiotics
Ampicillin (Penbritin®), erythromycin (Erythromycin lactobionate), tetracycline 
(Tetracycline®) (Chinoin, Budapest, Hungary)
3.6.4. Trifluoro-methvlketones (TF compounds’)
TF5: 3-trifluoroacetylindole (obtained from Tokyo Kaséi Kogyo Co. Ltd., Tokyo, Japan), 
TF6: 2-trifluoroacetylbenzoxazole [175],
TF10: 4,4,4-trifluoro-l-phenyl-1,3-butanedione [176.],
TF 11:1,1, l-trifluoro-3-(4,5-dimethyloxazol-2-yl)-2-propanone [176],
TF18: l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone [176],
TF19: 3-(2-benzothiazolyl)-l,1 ,l-trifluoro-2-propanone [177],
TF20: 3-(2-benzimidazolyl)-l,l,l-trifluoro-2-propanone [177],
TF50: 3,3,3-trifluoro-2-hydroxypropylphenyl ketone [175],
TF51: l-(2-benzoxazolyl)-2-propanone [175]
All compounds were dissolved in DMSO
3.6.5. Acridine derivatives: aza mono, bi- and tricyclic compounds
4-[(2 ’-Diethylaminoethyl)amino]-pyridine (2),
4-[(2 ’-Diethylaminoethyl) methylamino]-pyridine (3),
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7-Chloro-4-[(2 ’-diethylaminoethyl)amino]-quinolone (4), 
7-Chloro-4-[(2’diethylaminoethyl)-methylamino]-quinolone(5), 
6-Chloro-2-methoxy-9-[(2'-diethylaminoethyl)amino]-acridine (6), 
6-Chloro-2-methoxy-9-[(2 ’-diethylaminoethyl)methylamino]acridine (7),
2.8.10- Trimethyl-4,6-bis[N-(2 ’-diethylaminoethyl)-N-methylamino) ethoxy] pyrido-[3,2-g] 
quinoline (21)
(2,8,10-Trimethyl-bis-4,6-[N-(2’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] 
quinoline (24)
2.8.10- Trimethyl-6-phenoxy-4-[N-(2 ’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] 
quinoline (25) [178]
All compounds were dissolved in DMSO
3.6.6. Benzorbl-1.8-naphthvridine-5-one derivatives 
Benzonaphthyridine-5-one 10-(2’-dimethylaminoethyl) (1), 
Benzonaphthyridine-5-one 10-(3 ’-dimethylaminopropyl) (2), 
Benzonaphthyridine 5-one 10-(2’-diethylaminoethyl) (3), 
Benzonaphthyridine-5-one 10-(2 ’-diisopropylaminoethyl) (4), 
Benzonaphthyridine-5-one 10-(2‘-pyrrolidonoethyl) (5), 
Benzonaphthyridine-5-one 10-(2 '-(N-methyl)-pyrrolidinoethyl) (6), 
Benzonaphthyridine-5-one 10-(2’-piperidinoethyl) (7), 
Benzonaphthyridine-5-one 10-(3’-piperidinopropyl) (8), 
Benzonaphthyridine-5-one 10-(2’morpholinoethyl) (10).
All derivatives were tested as the hydrochloride salt and dissolved in PBS[179].
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4. METHODS
4.1. Determination of minimum inhibitory concentration ( MIC)
Dispensing and diluting of bacteria / compounds / reagents to a 96 well microplate were 
conducted with the aid of an 8 multi barrel pipette. First the half dilution series of the 
compounds was prepared on the plate in sterile physiological saline. An overnight preculture 
of the bacterial strain was diluted to 10'4 in 2x MTY broth (about 1.0 McF), and 50 pi of this 
bacteria suspension was added to the each 50 pi of the dilutions of the compounds on the 
microplate. The microplates were incubated at 37 °C for 24 hours. 10 pi of the solution of 
MTT (5 mg/ml in phosphate buffered saline (PBS)) was added to each well in order to 
evaluate the rate of bacterial growth. In this manner, mitochondrial dehydrogenase of living 
cells reduces MTT resulting in a blue coloured formazan salt. The plates were further 
incubated for 4 h at 37 °C, and then the MIC values of the compounds against the bacterial 
strain was determined. ... —
4.2. Checkerboard microplate method for evaluating the combined effect of two drugs 
[180]
The effect on bacteria of two drugs in combination can also be studied. The half dilution of 
drug 'A1 is made by the above mentioned method. No drug 'A' was put into 12th column 
(control of drug 'B'). The half dilution of drug 'B' is prepared in selected glasses and 50pl of 
each dilution was added to each well per row. The concentration of solutions decreases in the 
direction from up to down. No drug 'B' was added into H row (control of drug ' A'). The 
bacterial strains were cultured and diluted the same way mentioned above but lOOpl of 10'4 
diluted bacterial suspension was added into each well. The plates were incubated for 24 
hours at 37°C. MTT (10 pi) was added to the wells and incubated further 4 hours at 37°C. 
According to the colour of MTT the further rates can be determined: MIC values of drug 'A' 
and drug 'B' separately and MIC values of drug 'A' in combination and MIC values of drug 
'B' in combination. According to the further rates the effect of drug combination can be 
determined.
FICa= MICAComb / MICAalone FICb= MlCacomb / MlCealone
FIX= FICa + FICb
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0,51 < FIX < 1 -> additive effect; FIX < 0,51-» synergism; 1 < FIX < 2 -^indifferent 
effect; FIX > 2-» antagonism
4.3. Transformation of bacteria with pBR 322 plasmid
1 ml of an overnight YTB culture of an ampicillin and tetracycline sensitive bacterial 
strain was added to 100 ml YTB broth and incubated at 37°C until an optical density (OD) of 
0,25-0,30 at 600 nm was reached. The culture was transferred to an ice bath for 10 minutes, 
centrifuged at 4500 rpm for 10 minutes at 4 °C, then supernatant was removed and pellet re­
suspended in ice cold 50 ml 0.1 M MgSC>4, centrifuged in cold tube at 4500 rpm for 10 
minutes, the supernatant removed and the pellet was re-suspended in ice-cold 3.3 ml 0,1 M 
CaCh and incubated for 1 hour in an ice bath. 200 pi from these cultures containing the 
competent cells were transferred into tubes containing lpl of pBR322 (plasmid carrying the 
genes for ampicillin and tetracycline resistance) and the tubes kept in an ice bath for 30 
minutes and then rapidly transferred to 42°C for 1 minute in order that the cells be 
"shocked". One ml of YTB broth was added to the "shocked" cells and the tubes incubated 
for 1 hour at 37 °C. These cells were centrifuged in an Eppendorf centrifuge for a few 
seconds and 800 pi of supernatant removed. The cells were re-suspended in the remaining 
supernatant and an aliquot of 200 pi was plated onto YTB agar supplemented with 
tetracycline and ampicillin. Colonies present on these plates were indicative of containing 
the plasmid that bestowed them with resistance to ampicillin and tetracycline.
4.4. Method for elimination of pBR322 plasmid from E. coli AG100 and AG100A 
strains with replica plating
One colony of bacteria transformed with pBR322 plasmid was added to MTY broth 
media (5 ml) supplemented with glucose and MgS04 and incubated for 24 h at 37 °C. From a 
10'4 dilution of this overnight initial culture 2 ml was transferred to tubes containing 200 ml 
of MTY broth media, mixed, and distributed in 5 ml aliquots in test tubes. Different 
concentrations of curing compounds (compounds known to cause the elimination of 
plasmids) such as promethazine were added to the cells which were then incubated for 24 h 
at 37°C. 104 and 10s dilution of these cell suspensions were made and aliquots of 100 pi 
plated onto YTB agar and the plates incubated for 24 h at 37 °C. The colonies present on 
these Master plates were transferred by velvet replica plating technique onto YTB agar
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containing ampicillin and tetracycline (Replica plate). The plates were further incubated at 
37 °C 24 h after which time the distribution of colonies present in each of the respective 
plates was compared by simple over-laying methods. Colonies present on replica plates 
contain the pBR 322 plasmid which codes for resistance for ampicillin and tetracycline. 
Colonies present on the master plate and which do not grow on the Replica plate provide 
evidence of plasmid elimination promoted by promethazine or any other compound tested. 
Comparing the number of colonies on both plates provides an estimate of percent plasmid 
elimination (cure index) produced by a given compound.
4.5. Method for determining antimotility effect of drugs on P.vulgaris
From the overnight MTY culture of bacteria 100 pi was added to 900 pi of PBS 
which contains the drug in subinhibitory (sub MIC) concentration: 10, 90 and 50 percent of 
the MIC values of certain drugs were administered. PBS with no drug was used as a negative 
control and promethazine applied in the sub MIC concentration mentioned above was used 
as a positive control. The samples in Eppendorf tubes were incubated for 15 min at 37 °C. 
One drop of sample was placed on a microscopic slide and covered with 18 mm square 
coverslip. The preparation was examined with a phase contrast Zeiss microscope with 63x 
water objective in the case of P. vulgaris. 200-300 cells of P.vulgaris were totally counted 
from 4-6 fields using hand-tally counter. The motile (running), the non-motile and the 
vibrating (tumbling) cells were counted separately. The ratio of cells with different moving 
was expressed in percentage of untreated control.
4.6. Multidrug resistance reversal effect by decreasing Rhodamine 123 efflux
The L51478 mouse T cell lymphoma cell line was infected with the mdrl/A 
retrovirus, mdrl expressing cell lines were selected by culturing the infected cells with 60 
ng/ml colchicine to maintaine expression of the mdr phenotype. The L5178 MDR cell line , 
and the L5178Y PAR cell line were grown McCoy’s 5A medium with 10% heat-inactivated 
horse serum, L-glutamine (1 ml/100ml), streptomycin (1 ml/100ml) and nystatin (0.1 
ml/100ml). The cells were adjusted to a concentration of 2xl06 / ml and resuspended in 
serum free McCoy’s 5A medium and the cells were distributed into 0.5 ml aliquots to 
Eppendorf centrifuge tubes. Then the tested compounds were added in various 
concentrations of the 1.0 mg/ml stock solutions, and the samples were incubated for 10 min 
at room temperature. Then 10 pi (5.2 pM final concentration) indicator R123 was added to
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the samples, and the cells were incubated for a further 20 min at 37 °C, washed twice and 
resuspended in 0.5 ml PBS for analysis. The fluorescence of cell population was measured 
by flow cytometry with a Beckton Dickinson FACScan instrument. Verapamil was used as a 
positive control in the R123 exclusion experiments. The percentage of the control mean 
fluorescence intensity was calculated for PAR and MDR cell lines as compared to untreated 
cells. An activity ratio was calculated by the following equation on the basis of measured 
fluorescence values:
FAR (MDRtreated I MDR control) / (P ARtreated/ PAR control)
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5. RESULTS
5.1. Experiments on bacteria having proton pump transporter with resistance modifier
5.1.1 .The interaction of Ca-channel blockers (promethazine, (±lveranamil) and potential
proton pump inhibitor trifluoro-methvlketones on E. coli AG 100 and AG 100A strains
In preliminary experiments, the interaction of promethazine of potent antimicrobial 
effect and newly synthesised trifluoromethyl-ketones was evaluated on both strains 
respectively in agar diffusion method to use sterile filter paper strips containing 50 pg 
promethazine and 200 pg TF compounds. The strips containing promethazine and a 
representative of TF compounds were put at right angles to each other on the MTY agar 
containing the bacterial culture. After incubation the type of interaction was evaluated. TF 
50, 19, 20 were ineffective, TF 5 had very slight, TF 10 and 11 had strong and TF 18 had 
very strong synergistic effect with promethazine on both strain (data not shown). TF 11 had 
slight antibacterial effect on both strain, TF 10 exerted stronger inhibition only on mutant 
strain however TF 18 inhibited the growth of both strain strongly.
For the further studies of interaction the MIC values of promethazine and TF 
compounds were determined in broth dilution method (Table 1.)
Table 1. The MIC-values of Ca-antagonists, TF compounds and antibiotics on E. coli 
AG100 and AG 100A strains 
Compounds MIC values (pg/ml)
E. coli AG 100 (wild) E. coli AG 100 A (mutant)
promethazine
verapamil
TF18
TF10
TF50
156.25 78.15
500 250
7.8 3.9
31.25 7.8
1250 625
TF5 1250 39.1
TF51 313 156
TF20
TF19
TF11
TF6
ampicillin
teracycline
erythromycin
1250 1250
1250 312.5
62,5 31,25
1250 625
5 1.25
40 10
80 1.25
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Based on the preliminary experiments the three most effective TF compounds (TF 
10, 11 and 18) were examined in checkerboard experiments with promethazine. After 
determining the MIC values of compounds employing with or without combination, the FIX 
index was calculated which is characteristically for the phenomenon of the interaction. Data 
are shown on table 2.
Table 2. The interaction of promethazine with TF 10, 11, 18 and the combined effect of 
verapamil and TF 18 on E. coli AG 100 and AG 100A strains
Compounds MIC (pg/ml) in
E. coli AG 100 E. coli AG 100 A
Promethazine 156,25 78,15
TF 10
Promethazine + TF 10 
FIX index / interaction
31,25
78,15 + 7,8 
0,75 / ADDITIVE
7,8
39,05 + 3,9 
1,0/ADDITIVE
TF 11
Promethazine + TF 11 
FIX index / interaction
62,5 31,25
19,55 + 7,8 
0,5 / ADDITIVE
39,05 + 15,65 
0,5 / ADDITIVE
TF 18
Promethazine + TF 18 
FIX index / interaction
7,8 3,9
39,05 + 1,0 
0,38 / SYNERGY
19,55 + 1,0 
0,51 / ADDITIVE
Verapamil 
Verapamil + TF 18 
FIX index / interaction
500 250
125 + 15,63 
2,25 / ANTAGONISM
125 + 1,95 
1,0/ADDITIVE
According to the checkerboard technique synergistic effect between TF compounds and 
promethazine was exhibited only by the combination of TF 18 with the Ca-calmodulin 
channel blocker promethazine just on the proton pump expressing E. coli strain. TF 10, 11 
showed moderate combined effect on both E. coli strain. According to the experiments the 
most effective compound (TF 18 ) was examined further by the combination with the Ca- 
channel blocker (±)verapamil on both E. coli strain. Interestingly on the mutant strain the 
combination was additive however on the proton pump expressing wild strain an antagonism 
was demonstrated.
5.1.2. Elimination of pBR 322 plasmid from E. coli AG100 and AG100A strains by
promethazine
The calmodulin inhibitory promethazine is long known to have antiplasmid effect 
[164], We were wonder whether the existence of proton pump in the bacterial membrane can 
influence this phenomenon. The plasmid curing ability of promethazine was evaluated with
++ •
'-■l.'Z + j
■V?.
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the use of the two E. coli strains mentioned above transfected with pBR322 plasmid (tetr, 
ampr). As shown by Table 3, promethazine promotes the elimination of plasmids from the 
wild type E. coli strain in a concentration dependent manner such that the maximum curing 
effect takes place at a concentration just below the MIC of the compound (120 mg/1). In 
contrast to the wild type strain, promethazine causes elimination of plasmids from the proton 
pump-deleted mutant at lower concentration of the compound (80 vs. 140 mg/1).
Table3. Elimination of pBR 322 plasmid with promethazine from E. coli AG100 (wild) and 
AG 100A (mutant) strains.
Kcoli AG 100 (wild) E.coli AG 100 A (mut)
Colonies without 
plasmid (%)
promethazine (pg/ml)
0 0 0
40 0 0
60 0 0
80 0 11,0
100 MIC1,0
120 13,0
140 10,0
160 MIC
5.1.3.The interaction of potential proton pump inhibitor TF 18 and some representatives of
antibiotic groups on E. coli AG100 and AG100A strains
The further step was to study whether TF 18 can influence the antibiotic sensitivity of 
both E. coli strain. It is well known, that the AcrAB-TolC proton efflux pump has its 
antibiotic substrate of large hydrophobic characteristic e.g. erythromycin and tetracycline. It 
is proved on the Table 4., which shows the MIC values of antibiotics and TF18, in proton- 
pump-deleted and -expressing strain as well. Hydrophilic ampicillin was also employed as a 
control. According to the results of the checkerboard technique TF 18 at a concentration well 
below its MIC and in combination of tetracycline, erythromycin each of which is also well 
below its MIC, have a synergistic effect on the inhibition of both strain, however the lower 
FIX index in the case of proton-pump-expressing wild strain indicates the stronger 
synergism than that of in the case of proton-pump-deleted mutant strain. Remarkable that the 
MIC value of erythromycin which is proved to be the substrate of AcrAB-TolC proton efflux 
pump [84] decreased 32 fold in the presence of TF 18, in the proton-pump-expressing strain 
(from 80 mg/1 to 2,5 mg/1), however this decreasing was only 4 fold in the mutant strain.
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Expectedly the MIC values of ampicillin did not change significantly in combination with 
TF 18 in both strain.
Table 4. The interaction of TF 18 and some representatives (ampicillin, tetracycline, 
erythromycin) of antibiotic groups on E. coli AG 100 and AG 100 A strains
E. coli AG100ACompounds E. coli AG100
FIX values 
(type of 
interaction)
FIX values 
(type of 
interaction)
MIC valuesMIC values
(mg/1)(mg/1)
3.9TF18 7.8
1.255AMP
1.25 + 3.9 2.0 (indifferent)1.0 (additive)AMP+TF18 2.5+ 3.9
1040TET
1.25 + 0.98 0.38 (synergy)0.31 (synergy)2.5 + 1.95TET+TF18
1.2580ER
0.38 (synergy)0.3 + 0.50.28 (synergy)ER+TF18 2.5 + 1.95
5.1.4. Comparison of the interaction of erythromycin plus known proton pump inhibitor
Omeprasol with that of erythromycin plus the newly synthesised TF 18 - a potential
proton nump inhibitor-and with its structurally close derivative TF 51 on E. coli
AG100 and AG100A strains.
To determine the specificity of proton pump inhibitory effect, a known and two 
newly synthesised TF compounds were compared in the combination experiment with 
erythromycin on both E. coli strain. Data are shown on Table 5.
Table 5. Comparison of proton-pump inhibitor Omeprasol with TF 18 in combination with 
erythromycin on E. coli AG100 and AG100A
E. coli AG100AE. coli AG100Compounds
FIX values 
(type of 
interaction)
MIC valuesFIX values 
(type of 
interaction)
MIC values
(mg/1)(mg/1)
1,25Erythromycin 
TF 18 
TF 51 
Omeprasol
80
3,97,8
156313
25002500
0.29 (synergy) 
2.0 (indifferent)
0.28 (synergy) 
1.0 (additive) 
1.0 (additive)
0,5 + 0,2 
156 + 3,9 
2500 + 3,9 2.0 (indifferent)
1,95 + 2,5 
157 + 40 
1250 + 40
TF 18 + ER 
TF51+ER 
OMP + ER
As seen in the table 5. Omeprasol can influence the erythromycin sensitivity nor in the case 
of E. coli AG 100, neither in proton pump-deleted mutant. A very marginal inhibitory effect 
(additive effect, FIX-index= 1.0) takes place in E. coli operating with proton efflux pump.
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Exactly the same what is to explain about TF 51, however the structural differences between 
TF 51 and 18 are only a terminal H3 and F3 group in the side chain.
5.1.5. Combinations of antibiotics (erythromycin and ampicillin) with known resistance
modifiers (promethazine, verapamil! respectively on E. coli AG100 and AG100A
strains
After a newly synthesised potent resistance modifier trifluoro-methylketones (TF18) 
was found to be successful in reversing antibiotic resistance caused by a proton efflux pump, 
known resistance modifiers, the Ca-calmodulin-antagonists promethazine, and the Ca- 
antagonists verapamil, were employed in combination with erythromycin (substrate of 
AcrAB efflux pump due to its hydrophobic characteristic) and with ampicillin (surely not 
substrate of the Acr AB efflux pump due to its hydrophilic phenomenon) in the proton efflux 
pump-deleted and in the wild E. coli strains. Table 6 shows the results deriving from the 
checkerboard technique.
Table 6. Combined effect of ampicillin, erythromycin with Ca-antagonists promethazine, 
verapamil on E. coli AG100 and AG100A strains.
E. coli AG100AE. coli AG100Compounds
MIC values 
(mg/1)
FIX values 
(type of 
interaction)
MIC values FIX values 
(type of 
interaction)
(mg/1)
1,25Erythromycin 
Ampicillin 
Promethazine 
Verapamil 
Ery + PMZ 
Ery + VP 
Amp + PMZ 
Amp + VP
80
1,255,0
78,15156,25
250500
20 + 78,13 0,75/ADDITIVE 0,33 + 19,53 0,5/ADDITIVE
80 + 500 2 / INDIFFERENT 0,33 + 15,7 0,32/SYNERG.
5,0+156,25 2/INDIFFERENT 2,5 + 78,13 3 / ANTAGON.
2,52 + 250 1 /ADDITIVE 2,5 + 250 3 / ANTAGON.
In the wild type E. coli AG100 strain promethazine only slightly (in additive way), 
verapamil did not influence the sensitivity of erythromycin which is substrate of the pump of 
the bacteria. In the proton pump deficient bacteria the Ca-calmodulin antagonist 
promethazine caused a strong additive effect but not synergy, however the Ca-antagonist 
verapamil decreased the MIC of erythromycin to 0,33 mg/1 like promethazine did, but 
promethazine needed its 25% of MIC value (19,53 mg/ 1) for this interaction, however 
verapamil was able to reach the same only with its 5 % of MIC value (15,7 mg/1), namely 
the verapamil + erythromycin interaction is synergistic in the proton-pump deficient strain.
34
The sensitivity of ampicillin wasn’t influenced by both Ca-antagonists on wild strain, 
however interestingly promethazine and verapamil stood in antagonism with ampicillin on 
the mutant strain.
5.1.6. Inhibition of motility bv trifluoro-methvlketones on a clinical isolates of P. vulearis
The movement of bacterial flagellae is strongly energized by proton motive forces, so 
the fuel for movement comes from the energy of proton gradient (details in discussion). This 
fact was used to study TF compounds further, whether really having an effect on proton 
pumps and so being able to inhibit the movement of bacteria. Two types of movement were 
examined: the running and the tumbling and of course the non-motile cells. Since the drugs 
were used in subinhibitory concentrations, first the MIC values of TF compounds were 
determined (table 7.). Ren et al suggested that phenotiazines e.g. promethazine can inhibit 
the movement of bacteria by reversible inhibition on the proton pump of the bacterium. 
Using this hypothesis promethazine was used as a positive control also in subinhibitory 
concentration.
Table 7. MIC values of TF compounds and promethazine on P. vulgaris
MIC values (mg/1)Compounds
6,3TF 18 
TF 10 
TF 11
12,5
156,2
625TF 6
625TF 5
625TF 51 
TF 20 
TF 19
promethazine
1250
1250
156
In preliminary experiments the strain of P. vulgaris was incubated with 10, 50 and 90 % of 
MIC of TF 18 for 15 min at 37 °C respectively, then the suspension was plated on an agar 
plate. No drug was used as a negative control. Counting the number of colonies grown, there 
were not significant differences between the treated and untreated samples, indicating that 
the treatment with the sub-MIC concentration of TF 18, in a short period, does not influence 
the growth of bacteria.
In the antimotility experiment the average distribution of untreated Proteus movement was 
the following: 64.5± 10 % running, 28.9±8 % tumbling and 6.6± 3 % non-motile, 
respectively. Compounds 5,19, 20 at 10 % of their MIC partially inhibited the motility: the
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ratio of running cells decreased, however one of the tumbling cells significantly increased. 
The number of non-motile cells increased somewhat only in the sample treated with TF5 at 
10 % of MIC. However TF 5, 19, 20 had solubility problems and formed slight opalescence 
which could inhibit the bacterial motility. TF 6,10,11,18 and 51 could exert real inhibition 
of moving: the ratio of non-moving cells treated with these compounds increased 
significantly. In the case of TF 6 and 18 the number of tumbling cells also changed however 
TF10, 11 and 51 didn’t alter them significantly. The correlation between concentrations 
applied and antimotility effect was significant in the case of TF 6, 18 and 51. Less 
correlation was observed with TF 11 and no correlation could be established with TF 10. TF 
18 exerted the most remarkable inhibition of movement: the ratio of non-moving cells 
increased significantly in a concentration- dependent manner. Already at 50% of its MIC no 
cells were running and at 90 % of its MIC 90,9 % of bacteria were totally non-motile and 
only 9,1 % of the cells showed tumbling without running. As it was expectable among eight 
TF compounds TF 18 was the most promising drug, with a strong antimotility effect on P. 
vulgaris (Figure 7.) reinforcing its proton pump inhibitory action supposed in earlier 
interaction studies.
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Figure 7. The antimotility effect of TF compounds and the positive control promethazine on 
P. vulgaris
5.2. Experiments with tumour cells having ABC transporter and resistance modifier
agents
5,2.1. Reversal of multidrug resistance in mouse lymphoma cells by mono, bi and tricyclic
acridine derivatives
Acridine compounds and other tricyclic derivatives have already been tested and 
several derivatives have interesting anti MDR activity (Hever et al). The aim of these 
examinations was to clarify the functional groups, which actually interact with the P-gp 170 
protein. Several variations have been made concerning: 1. the aromatic moiety e g. pyridine 
(2,3), quinoline (4,5), acridine (6,7) and pyridoquinoline (21, 24, 25) derivatives have been 
investigated, 2. the side chain has been modified e g. X atom nature (O, N or S) and / or size 
of the side chain (see chemical structure in annex, chapter 2 and 3.).
In the Rhodamine 123 accumulation assay on the L5178 mouse lymphoma cell line the 
follow were found (Figure 8.): the two examined pyridine derivatives namely 2 and 3 are 
inactive. Quinolines 4 and 5 are as active as positive control verapamil. The amino- 
substituted compound, 5 has a little better activity than the non substituted 4 at 2 mg/1 
concentration. High activity is observed for tricyclic derivatives. Acridine derivatives 6 and 
7 present a similar activity at low concentration but the non-substituted compound, 6 could 
be toxic at high doses. Among pyridoquinolines 24,25 exerted the best activity.
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Figure 8. MDR reversal effect of tricyclic compounds, where 2, 3 are aminopyridine, 4, 5 
are aminoquinoline, 6, 7, 21 are aminoacridine derivatives.
The most active compounds -6, 7, 21, 24 and 25 were examined at 0,2 and 2 mg/1 
concentration as well.
Figure 9. MDR reversal effect of the most active tricyclic compounds at lower 
concentrations
As seen on Figure 9. 6, 7 and 21 had no anti MDR activity at 0,2 mg/1 concentration, 
however 24 and 25 exerted the strongest anti MDR effect among tricyclic derivatives even at 
0,2 mg/1 concentration. The lower fluorescence activity ratio values in higher doses can be 
due to potential toxicity.
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5.2.2. Reversal of multidrug resistance in mouse lymphoma cells by benzo [bl-1.8-
naphthvridine derivatives
Because of its structural similarity with acridines, benzonaphthyridine nucleus was 
selected to study the efflux pump inhibitory effect.
Among compounds tested 1 had very weak anti MDR effect at both concentrations.2, 4, 7 
exerted strong reversing activity only at the higher 20 mg/1 concentration. 5, 6 and 8 showed 
the most promising MDR-reversing activity at lower concentration as well in comparison 
with reference drug verapamil. 5 being the most active of the set and was probably toxic in 
higher doses. It is important that all of these derivatives (namely 5, 6 and 8) are substituted 
with an azaheterocyclic group (Figure 10.).
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Figure 10. MDR reversal effect of benzonaphthyridine-5-one derivatives, where 5 was toxic 
at 20 mg/1 concentration
40
6. DISCUSSION
6.1. Experiments on bacteria having proton pump transporter with resistance modifier
agents
In the clinical practice with the more and more frequently appearing multiresistant 
bacterial strains, causing lethal infections due to therapeutic failure, there has been urging 
need to solve this world-wide problem. The solution can be the introduction of new 
antibiotics, but the inhibition of resistance mechanisms by known and newly synthesised 
resistance modifier agents might be cheaper and more effective.
Earlier it was found, that well-known psychotropic drugs, e.g. phenotiazines have 
antibacterial and antiplasmid effect [162,164,166,168,170,181].
Since the elimination of plasmids never occurs in the whole bacterial population, a more 
effective mechanism was chosen for reversing drug resistance: the inhibition of drug efflux 
pumps by chemical agents.
6.1.2. Combined effect of known and newly synthesized resistance reversing agent and some
representatives of antibiotics on E. coli AG100 and AG100A strains. The correlation
between chemical structure of TF compounds, and their antibiotic resistance reversing effect.
The newly synthesised trifluoro-methylketones have already been shown to have a 
strong inhibitory effect against Helicobacter pylori compared with clinically used 
metronidazole and clarithromycin [182]. Taking further this evidence we examined whether 
they have antibacterial effect on other bacteria and their resistance reversal ability by 
inhibition of proton efflux pump was also examined.
Among the nine TF compounds, TF 18 (l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone) 
derivative exerted the strongest antibacterial activity on the proton pump-bearing and - 
mutant E. coli strains as well. Since TF10, 11 and 51 derivatives have also quite low MIC 
values on both strain, these four compounds were examined further in combination 
experiments. Only TF 18 showed some effect on the wild type E. coli strains combined with 
known resistance modifier promethazine and verapamil respectively, namely it potentiated 
the antibacterial action of promethazine indicating that this phenothiazine can be a target of 
the efflux pump, however with verapamil the combination was an antagonism suggesting, 
that TF 18 probably makes difference between the calmodulin-antagonistic and Ca-channel 
blocker property and the proton pump has some role on these effects [183].
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After transformation of the two E. coli strains by pBR322 plasmid, practically two strains 
were observed considered clinical resistant strain. Elimination of the plasmid by 
promethazine from both strain showed that promethazine could be the substrate of the 
AcrAB efflux pump, since the maximal elimination rate was significantly higher in wild type 
than mutant one, and that’s why the presence of this efflux pump could influence the 
plasmid elimination with promethazine. Later it was shown that the plasmid curing effects of 
promethazine, trifluoperazine and 9-aminoacridine were increased in the presence of a 
trifluoroketone proton pump inhibitor, TF 18, on E. coli K12 LE140 strain in a model 
experiment, where compound TF 18 alone didn’t exert antiplasmid effect [184]. It is 
proposed that the inefficient penetration of antiplasmid compounds could be responsible for 
the weak plasmid-curing effect in some clinical isolates, and that membrane active, 
calmodulin- and proton pump inhibitors may be combined for plasmid curing in antibiotic- 
resistant bacteria.
Considering the evidence, that the erythromycin is the substrate of AcrAB efflux pump due 
to its large hydrophobic characteristics [84], this antibiotics and the similar tetracyclin were 
combined with TF 18 on both E. coli strain. The hydrophilic ampicillin (with this 
phenomenon not substrate of AcrAB pump) was also employed as a control. TF 18 
decreased the MIC value of erythromycin 32 fold in wild strain (FIX index= 0,28 / strong 
synergy), and only 4 fold in mutant strain (FIX index= 0,38 / slighter synergy). Tetracycline 
and TF 18 also showed a synergism, however -as it was expected- the MIC value of 
ampicillin wasn’t influenced by TF 18 significantly. These results indicate that TF 18 really 
can have a special effect on inhibiting this proton efflux pump. The slighter synergy of TF 
18 and erythromycin on proton pump-deleted mutant strain can be explained only by the fact 
that TF 18 itself also has a strong antibacterial effect. As far as the ampicillin is considered, 
the differences between the two strains in MIC values cannot be explained directly by the 
presence / existence of proton efflux pump, all the more by the membrane permeability 
differences which is due to the efflux pump.
Comparison of the effect of TF 18 with other proton pump inhibitors e.g. omeprasol and the 
structurally related TF 51 it was observed, that omeprasol and TF 51 had only additive effect 
with erythromycin on the wild strains (FIX index=l,0 / additive effect) indicating having no 
or very slight proton pump inhibitory effect on the AcrAB efflux system. However the 
structural differences between TF 18 and TF 51 are only a terminal F3 and H3 groups in the 
side chains of the benzoxazole ring. Considering these results an evidence is suggested that
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the AcrAB efflux pump needs a certain structural requirement in the group of proton pump 
inhibitors for its successful inhibition.
Finally two known resistance modifier agents were examined in combination with the 
former antibiotics on the two E. coli strains. Neither of them could exert similar decreasing 
in MIC values of erythromycin on proton pump positive strain what TF 18 could. 
Interestingly the Ca-channel blocker verapamil was synergistic with erythromycin on the 
proton pump-deficient strain. This phenomenon can be explained by a changing effect of 
verapamil in the membrane permeability, which cannot be specific for its Ca-antagonistic 
property, since the Ca-calmodulin antagonistic promethazine did not show similar effect 
(additive with erythromycin on mutant strain). Interestingly the ampicillin with both Ca- 
antagonists stood in antagonism in mutant strain namely the Ca-channel blockers somehow 
could decrease the membrane permeability. Moreover the effect of verapamil on mutant 
strain can be in correlation with the properties of the antibiotics combined with. With 
hydrophobic erythromycin synergism, with hydrophilic ampicillin antagonism effect was 
found indicating the difference membrane permeability requirements of the two different 
type of antibiotics.
Comparing first the chemical structure of the trifluoro-methylketones examined for 
antibacterial effect it is suggested that the replacement of the benzoxazol residue of the most 
potent TF18 with other aromatic or heteroaromatic rings with intact side chain (resulting 
TF19,20) caused strong decrease in antibacterial action indicating that the benzazole 
derivatives were more active than either benzene or azole derivatives [183]. However after 
the TF 18 the most potent TF compound is TF 10 having only a benzole ring instead of 
benzoxazol, but its side chain bears an additional carbonyl group directly next to the ring 
which could mean the antibacterial efficacy. However next to intact rings the side chain 
could have also role in antibacterial effect, since removal of the terminal F3 from TF 18 to 
H3 resulting TF51 causes approximately 40 fold increasing in MIC values of both E. coli 
strain. Removal the methylene from the side chain of TF 18 resulting TF6 directs to 160 fold 
increasing in MIC of both strain. Summarized the structure of the benzoxazole ring and the 
side chain found in TF18 are together similarly important for the antibacterial action of 
trifluoro-methylketones. In combination experiments the three TF compounds (TF10,11,51) 
next to TF 18 were applied having the lowest MIC values. Considering the results obtained, 
it is sure that the side chain with its terminal F3 group is essential for proton pump inhibition 
but the benzoxazol ring has to be also some role in drug reversary action, since TF11 wasn’t 
effective in combination experiments. Further evidences were obtained between chemical
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structure of trifluoro-methylketones and their proton pump inhibitory effect in antimotility 
experiments.
6.1.3. Inhibition of motility on P. vulearis
For reinforcing the finding, that some TF compounds exert their resistance modifier 
effect by inhibition of proton pump, the antimotility effect of these drugs was studied on a 
clinical isolates of a P. vulgaris strain.
It is well known that the fuel for rotation of bacterial flagellae is the membrane gradient of 
protons [185,186]. The flagellar motor can rotate counterclockwise (CCW), where the 
several filaments on a cell join in a bundle and drive the cell forward resulting the running 
movement. In the case of clockwise (CW) rotation of flagellae the filaments bundle are 
disrupted causing a somersaulting movement or tumbling. Cells can direct their movement 
by regulating switching between CW and CCW rotation [187,188]. The torque for flagellar 
rotation is generated at the base [189,190]. The basal body functioning as a motor contains 
the essential proteins for moving: the so-called non-rotating stator complex comprises Mot A 
and Mot B membrane proteins which function together to conduct ions (protons) across the 
membrane [191-196]. The rotating part of basal body is the rotor or switch complex [197]. It 
contains the Fii M protein having main role in CW/CCW switching [198], the Fii G main 
rotor protein with any additional interacting, role mainly with the stator Mot A 
[199,200,201], and Fii N with structural role [202]. The motors can convert chemical energy 
into mechanical energy: as rotation is driven by cyclic conformational changes in the stator, 
which occurs as protons bind to and dissociate from a critical and essential Asp residue of 
Mot B. So this residue is essential for rotation and involved directly in proton transfer. The 
conformational changes would regulate access to the Asp 32 site to ensure that protons 
entered the site from periplasm and departed to the cytosol. The conformational changes in 
the stator would apply forces to the rotor, most likely on Fii G [203].
After the explanation the role of proton motive forces in the motility of bacteria, the 
supposed proton pump inhibitor TF compounds were tested whether having antimotility 
effect. With this phenomenon the reversal of antibiotic resistance could be attributed to 
proton pump inhibitory effect.
Earlier it was shown that the known resistance modifier promethazine has antimotility effect 
[204,205]. After studying the newly synthesized TF compounds with possible resistance 
reversary effect, some connections were established. In the case of badly soluble compounds 
(TF 5,19, 20) the strong decreasing in the number of motile bacteria can only possible due
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to the increased viscosity of media because of solubility problems as the rotation speed 
varies inversely with viscosity of the medium [206]. Among TF compounds having real 
antimotility effect of different efficacy only TF 18 and 51 showed significant antimotile 
effect at 10 % of MIC. At 90 % of MIC also TF 18 and 51 were the most effective in 
concentration-dependent manner as the ratio of non-motile cells were 90,9 % and 47,6 % 
respectively (in the case of promethazine 26,5 %). TF 6 worked also in concentration- 
dependent manner however only the number of tumbling cells increased significantly with 
decreasing of running ones. Taking as a basic of molecular structure of most effective TF 18, 
it is suggested that the benzoxazol ring is essential for antimotile effect as ring substitution 
next to intact side chain strongly decreased this efficacy. Among molecules having the 
original ring complex (TF 6, TF 51) with substituted side chains antimotility effect was more 
expressed. However in the side chain when terminal trifluorid was substituted with H3 group 
(resulting TF 51) antimotility effect was weaker. Probably the terminal trifluorid with 
benzoxazol ring is essential for strong antimotility effect and maybe for the proton pump 
inhibition as well. When the molecule of TF 18 was modified by extraction of the methylene 
group from the side chain (resulting TF 6), only the number of tumbling cells increased, the 
number of non-motile cells didn’t change significantly. It indicates that this structure may 
have a role in intervention into the CCW/CW switching and the methyl group may be 
important for the effective proton pump inhibition. Interestingly in the case of TF 18 with 
the increasing of applied concentration first the running cells decreased with increasing 
number of tumbling ones next to no significant alteration of non-motile ones and with 
further increasing of drug concentration practically the tumbling cells became non-moving. 
Summarized a progressivity is phenomenal for the antimotility effect of TF18: first the 
running cells become tumbling and later, with increasing of drug concentration, the tumbling 
ones become non-motile. It is evidence that the inhibition of motility can be by proton pump 
inhibition and / or decreasing proton motive forces. However it is not closed that the CCW / 
CW switching and its influence comprises operation of proton pumps / proton motive forces. 
Taking these suggestions TF 18 can be considered a drug having real proton pump inhibitory 
effect reinforcing the mechanisms by which TF 18 works as an antibiotic resistance 
reversing agents.
Other importance of the finding is the inhibition of motility - as a potent virulence factor - 
itself. It was previously reported that TF 18 inhibited H. pylori growth in vitro [207]. H. 
pylori is a strongly motile bacterium [208], and the motility conferred by the flagella is 
necessary for colonization in the gastric mucosa and development of gastritis by H. pylori
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[209,210]. Therefore, in the stomach there are some connections between the pathogenecity 
and the active moving of H. pylori. Recent studies have provided evidence that motility in H. 
pylori was also suppressed by the proton pump inhibitors such as rabeprazole [209,210]. In 
this study, it is suggested that TF compounds may have an inhibitory effect against the in 
vitro motility of H pylori. The inhibition of bacterial motility can be related with the 
virulence of bacteria: the pathogenicity can be decreased in the presence of drugs examined. 
In the case of nephropathogenic E. coli strains the active moving has a role in wandering of 
bacteria from the lower urine tract, bladder to upper tract via urether to cause chronic 
pyelonephritis [211]. The adhesive pili have also role in sticking of bacteria. It was proved in 
electromicroscopic experiments that the function of pili can be inhibited by specific 
compounds: pili-specific phages failed to adsorbate [212].
Among Gram-negative bacteria the intrinsic resistance for some typically „Gram-positive 
antibiotics” e.g. erythromycin and for some unrelated drugs, is due to the working of an 
efflux pump system which uses proton gradient for its operation and work in synergy with 
outer membrane barrier. The successful inhibition of this proton pump by l-(2- 
benzoxazolyl)-3,3,3-trifluoro-2-propanone (TF 18) means the possibility to employ an 
earlier ineffective antibiotics with a pump inhibitor in combination. The experiments show, 
that a so-called „Gram-negative resistance” can be overcome by this method.
6.2. Experiments with tumour cells having ABC transporter and with resistance
modifier agents
In the clinical practise to avoid the selection of resistant tumour cells combined 
chemotherapy has to be employed. Theoretically the co-administration of cytostatic drugs 
with the proper resistant modifier agent could be also a possible and cheaper way to 
overcoming multidrug resistance and the therapeutic failure.
A plenty of structurally unrelated resistance modifier drugs were found which can 
inhibit drug efflux pumps of tumour cells. 3,5-diacetyl-1,4-dihydropyridines were effective 
to reverse multidrug resistance in mouse lymphoma cell line operating with the P- 
glycoprotein-170 (P-gp 170) efflux pump protein [213]. On the same laboratory cell line this 
efflux pump was successfully inhibited by heterocyclic compounds e.g. phenotiazines [214], 
thioacridine derivatives [215], anti-psychotic drugs [216]. Among plant derivatives some 
carotenoids [217], diterpenes and triterpenes [218] were also shown to inhibit MDR efflux 
proteins in mouse lymphoma and human breast cancer cell lines as well. Several plant 
extracts derived from ‘Anastasia Red’ sweet pepper fruits [219], from Persimmon Diospyros
46
kaki peels [220], and Allium victorialis total herbs [221] exerted strong anti-MDR activity on 
mouse lymphoma cell line. Feijoa peel extracts had only marginal effects [222]. Since these 
extracts are chemically not entirely characterized, further additional analysis are needed for 
finding the structure-activity relationship.
In general the chemosensitizers that block P-gp drug extrusion are lipid-soluble at 
physiological pH, possess a basic nitrogen atom and at least two co-planar rings [127], have 
aromatic moieties, but the presence of electron donor groups is a more general feature [223].
6.2.1. Reversal of multidrug resistance in mouse lymphoma cells bv mono, bi and tricyclic
acridine derivatives
To summarize the results, it was shown that anti MDR activity depends on the 
aromatic moiety, the bonded X heteroatom and nature of the side chain. A better activity is 
found: when the aromatic moiety is acridine or pyridoquinoline compared with quinoline 
and pyridine. It can be questioned whether log P (or log D) are related to the activity. If the 
values for pyridine compounds are low (<2) compared with all other products, the calculated 
values for quinoline compounds 4 and 5 (3,32 and 3,70) are in the same range of an active 
pyridoquinoline and even higher than that of an other, nevertheless very active 
pyridoquinoline [178]. The lack of direct correlation between log P and anti MDR activity 
has previously been underlined [224]. If we consider the compound activity related to the 
number and length of the side chain -keeping the same X atom on the ring- activities are in 
the following increasing order: when X=0 I5[178]< 21, when X=N 20[178] < 24 < 25, that 
is 2 side ‘short’ chains<one side ‘short’ chain or two side ‘long’ chains (see Annex chapter 
3.). For compound 21 a better activity ensues since its side chain is longer with an additional 
electron donor group (diethylaminoethyl ring) compared with the other disubstituted 
pyridoquinolines 15 [178].
Considering more than 100 compounds already tested [225], activities have been correlated 
with the presence of two or three hydrogen bond acceptor (HBA) groups with a spatial 
separation of 2,5 or 4,6 Á. For the products studied here, possible HBA groups are tertiary 
amino groups, heterocyclic nitrogen. When X= N (see Annex chapter 3.) e.g. in the case of 
24 and 25, the heterocyclic nitrogen potency is increased by a push-pull effect [226].
In addition to its nitrogen HBA group, the heterocycle can interact with P-gp by aromatic 
hydrophobic interaction. The lack of activity of pyridine and quinoline derivatives 2-5 seems 
to indicate that hydrophobic interactions are rather involved. Differences in the observed 
activities of the compounds can be attributed to the spatial position of the amino HBA
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groups and aromatic rings. The results display that two long chains allow the best 
interactions between compound pharmacophoric groups and P-gp binding sites (Figure 11.).
Figure 11. A possible superimposition of 
pyridoquinoline derivatives (in bold) and acridine 
derivatives when interacting with the P-gp
® HBA group
6.2.2. Reversal of multidrug resistance in mouse lymphoma cells by benzo Tbl-1,8-
naphthyridine derivatives
Tricyclic derivatives including phenotiazines and acridines are among compounds 
showing anti MDR activity [214, 215]. Unfortunately, most of these agents suffer clinically 
from their intrinsic toxicity or from side-effects at concentrations which neutralise P-gp 
[227], So to design new inhibitors active at low concentrations and free of serious side- 
effects is vital. Benzonaphthyridine nucleus was selected because of its structural similarity 
with acridines, the more so as compounds in this chemical series are usually less toxic than 
acridines..
According to the data received there is clear evidence that benzonaphthyridine derivatives 
increased accumulation of Rhodamine-123 in MDR cells more efficiently than phenotiazines 
and acridine derivatives, or the positive control verapamil did. Since the hydrophobic moiety 
could be essential in the activity of MDR modulators, benzonaphthyridine derivatives with 
the polycyclic nucleus modified in various ways were tested. The activity of 
benzonaphthyridine derivatives with various side-chain was compared with the aim of 
determining the effect of the nature of this chain on the MDR reversion. Compounds 5, 6, 8 
and 10, which bore saturated aza heterocyclic moieties (pyrrolidine, morpholine, piperidine), 
were the most active at the lowest concentration. In addition, the presence of the amino 
group protonatable in the physiological conditions seemed to be necessary for the reversion 
of MDR in the case of tricyclic derivatives. This is clearly demonstrated by comparing 3 to 
11. Indeed, there is the same lipophilic moiety in both compounds but there is an acetamido 
group in the side-chain of 11 whilst the amino group is protonatable in 3. Similar results 
were obtained by Hever et al for acridine derivatives [215].
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7. CONCLUSION
1. Among trifluoro-methylketones, 4,4,4-trifluoro-1 -phenyl-1,3-butanedione (TF10), 
l,l,l-trifluoro-3-(4,5-dimethyloxazol-2-yl)-2-propanone (TF11) and l-(2-benzoxazolyl)- 
3,3,3-trifluoro-2-propanone (TF18) has the strongest antibacterial effect on E. coli AG 100 
wild and on E.coli AG100A proton pump deleted mutant strain as well.
2. a.) 4,4,4-trifluoro-1 -phenyl-1,3-butanedione (TF10) and l,l,l-trifluoro-3-(4,5- 
dimethyloxazol-2-yl)-2-propanone (TF11) showed moderate combined effect on both E. coli 
strain in combination with Ca-calmodulin antagonistic promethazine. l-(2-benzoxazolyl)- 
3,3,3-trifluoro-2-propanone (TF18) exerted synergy with promethazine only on the wild E. 
colt strain indicating that this phenotiazine can be a target of the AcrAB efflux pump.
b.) The most effective trifluoro-methylketone, l-(2-benzoxazolyl)-3,3,3-trifluoro-2- 
propanone (TF18) was studied in interaction with Ca-channel blocker verapamil. On mutant 
strain the combination was additive, however on the wild strain an antagonism was found. It 
is suggest that TF 18 probably makes differences between the calmodulin-antagonistic and 
Ca-channel blocker property, and the proton pump has some role on these effects.
3. Promethazine eliminated the pBR322 plasmid at a maximal rate from mutant strain at 
lower concentration than from the wild type indicating that the presence of this efflux pump 
can influence the plasmid elimination with promethazine.
4. l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone (TF18) decreased 32 fold the MIC 
value of erythromycin in wild, and 4 fold in mutant strains respectively. The sensitivity of 
ampicillin did not change significantly in combination with TF 18 in both strain. It indicates 
that TF 18 does have a special effect on inhibiting this efflux pump. The weaker synergism 
of TF18 and ER in mutant strain can be explained by the strong antibacterial effect of TF18.
5. Different proton pump inhibitors were compared in combination with erythromycin 
on both strains. Neither Omeprasol and nor l-(2-benzoxazolyl)-2-propanone (TF51) 
decreased the sensitivity of erythromycin on both strain indicating that there is a certain 
structural requirements for the inhibition of AcrAB efflux pump.
6. Known resistance modifiers were combined with antibiotics on both E. coli strains, 
a.) Erythromycin with promethazine was additive on wild and mutant strain as well.
Erythromycin with verapamil was indifferent on wild strain, however on mutant strain this 
combination was synergystic. The latter phenomenon is explained by a changing effect of 
verapamil in the membrane permeability, which cannot be specific for its Ca-antagonistic 
property, since the Ca-calmodulin antagonistic promethazine did not show similar effect.
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b.) The ampicillin with both Ca-antagonists stood in antagonism in mutant strain, 
namely the Ca-channel blockers somehow could decrease the membrane permeability in this 
strain. The effect of verapamil on mutant strain depends on the property of antibiotics 
combined with VP: with hydrophobic erythromycin synergism, with hydrophilic ampicillin 
antagonism were found, indicating the difference membrane permeability requirements of 
the two antibiotics.
7. Among trifluoro-methylketones the motility of P. vulgaris was inhibited by the 
strongest way by -(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone (TF18) reinforcing its 
proton pump inhibitory action supposed in the interaction studies. Furthermore a 
progressivity is phenomenal for the antimotility effect of TF18: first the running cells 
become tumbling and with increasing of the drug concentration, the tumbling ones become 
non-motile.
8. For the strong antibacterial, antimotility and so for the proton pump inhibitory effect 
of the trifluoro-methylketones, the structural requirements are the follows: 1 .presence of the 
benzoxazol ring, since benzazole derivatives were more active than benzene or azole ones 
next to intact side chain. Next to the presence of benzoxazol ring 2. presence of side chain 
found in TF 18 is essential, since removal of terminal F3 group, methylene group resulted 
drastic decreasing the antibacterial and antimotility action as well.
9. The MDR reversal activity of acridine derivatives depends on the aromatic moiety, 
the bounded heteroatom and nature of the side chain. Better activity is found: when the 
aromatic moiety is acridine or pyridoquinoline compared with quinoline and pyridine. 
Keeping the same atom on the ring, derivatives, having two side long chains, are more 
effective than ones, having one side short chain. Anti MDR activity was correlated with the 
presence of two or three hydrogen bond acceptor (HBA) groups. Possible HBA groups are 
tertiary amino groups, heterocyclic nitrogen like in the case of 2,8,10-Trimethyl-bis-4,6-[N- 
(2’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] quinoline (24) and 2,8,10-Trimethyl- 
6-phenoxy-4-[N-(2’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] quinoline (25). In 
addition to its nitrogen HBA group, the heterocycle can interact with P-gp by aromatic 
hydrophobic interaction.
10. The activity of benzonaphthyridine derivatives with various side-chain was compared 
with the aim of determining the effect of the nature of this chain on the MDR reversion. 
Compounds, which bore saturated aza heterocyclic moieties (pyrrolidine, morpholine, 
piperidine) were the most active. The presence of the amino group protonatable in the 
physiological conditions seemed to be necessary for the reversion of MDR.
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8. SUMMERY
With the more and more emerging multidrug resistance problem, there is urgent need 
to research the cause, nature, and spread of the resistance, and to find some solutions for 
reversing MDR both in bacteria and tumour cells. One of the solutions is to develop new and 
more effective antibiotics and citostatics, but in a few time the appropriate resistance 
mechanism will arise to make the drugs ineffective. An other way for preventing the 
appearance of multidrug resistance is the application of combined chemotherapy, 
particularly in treatments of long-time duration e.g. certain type of cancers and tuberculosis. 
However it is better, when the resistance mechanisms are inhibited by some chemical agents. 
During the treatments of bacterial infections there already have been a method working with 
reversing of resistance, where the P-lactam antibiotics are combined with p-lactamase- 
inhibitors e.g. amoxicillin + clavulanic acid, ampicillin + sulbactam or piperacillin + 
tazobactam. Theoretically the elimination of plasmids carrying the resistance genes could 
also mean a solutions, however the elimination never occurs in the whole bacterial 
population. A better solution is to inhibit such a resistance mechanism, where the inhibition 
exists among all the cells of the population. The inhibition of bacterial and tumour multidrug 
efflux pumps by some chemical agent can be a practicable plan to overcome MDR. Among 
Gram-negative bacteria the intrinsic resistance for some typically „Gram-positive 
antibiotics” e.g. erythromycin and for some unrelated drugs, is on the one hand due to the 
working of an efflux pump system which uses proton gradient for its operation. The 
successful inhibition of this proton pump by l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone 
(TF 18) means the possibility to employ an earlier ineffective antibiotics with a pump 
inhibitor in combination. The experiments show, that a so-called „Gram-negative resistance” 
can be overcome by this method. The way of the reversal mechanism, namely the inhibition 
of proton pump by TF 18, was proved by the successful inhibition of bacterial movement.
The reversal of drug resistance by inhibition of P-glycoprotein 170 efflux pump in mouse 
lymphoma cells was successful with chemically unrelated agents as well. The relationship 
found between the biological activity and chemical structures provides information for the 
further drug design research. The results are derived from model experiments. All the new 
information received can serve as a building stone in the research field of multidrug 
resistance reversary. First of all the statements of structure-activity relationship may be 
important for further drug design, which involves the synthesis of more effective and less 
toxic compounds and for in vivo experiments in the future.
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ANNEX
1. Chemical structures of trifluoro-methylketones
OCH 2COCF 3
COCF 3
TF6 TF10
ch2cocf3ch2cocf3 ch2cocf3
TF19TF18
_ °
^^-CCHsCHCFa CH 2COCH 3CH2COCF3
OH
TF20 TF60 TF61
5: 3-trifluoroacetylindole (obtained from Tokyo Kaséi Kogyo Co. Ltd., Tokyo, Japan), 
6: 2-trifluoroacetylbenzoxazole [175],
10: 4,4,4-trifluoro-l-phenyl-1,3-butanedione [176.],
11:1,1, l-trifluoro-3-(4,5-dimethyloxazol-2-yl)-2-propanone [176],
18: l-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone [176],
19: 3-(2-benzothiazolyl)-l, 1,1 -trifluoro-2-propcmone [177],
20: 3-(2-benzimidazolyl)-l, 1,l-trifluoro-2-propanone [177],
50: 3,3,3-trifluoro-2-hydroxypropylphenyl ketone [175],
51: l-(2-benzoxazolyl)-2-propanone
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2. Chemical structures of acridine derivatives: aza mono, bi and tricyclic compounds
2 3
r
2: 4-[(2 ’-Diethylaminoethyl)amino]-pyridine
3: 4-[(2’-Diethylaminoethyl) methylamino]-pyridine
4: 7-Chloro-4-[(2 ’-diethylaminoethyl)amino]-quinolone
5: 7-Chloro-4-[(2’diethylaminoethyl)-methylamino]-quinolone
6: 6-Chloro-2-methoxy-9-[(2 ’-diethylaminoethyl)amino]-acridine
7: 6-Chloro-2-methoxy-9-[(2 ’-diethylaminoethyl)methylamino]acridine
21: 2,8,10-Trimethyl-4,6-bis[N-(2'-diethylaminoethyl)-N-methylamino) ethoxy] pyrido-[3,2-
g] quinoline
24: 2,8,10-Trimethyl-bis-4,6-[N-(2 ’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] 
quinoline
25: 2,8,10-Trimethyl-6-phenoxy-4-[N-(2 ’-diethylaminoethyl)-N-methylamino] pyrido-[3,2-g] 
quinoline
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3. Chemical structures of acridine derivatives: aza mono, bi and tricyclic compounds 
with regard the X atom in the side chain
k
X = 0, 21
2: X = NH 
3 : X = NMe
4 : X = NH
5 : X = NMe
6: X = NH 
7: X = NMe.
r
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4. Chemical structure of Benzo [b]-l,8- naphthyridinc derivatives
Type of nucleusCompounds R’R
10-(2 ’ -dimethylaminoethyl)
10-(3 ’ -dimethylaminopropyl)
10-(2’-diethylaminoethyl)
10-(2’-diisopropylaminoethyl)
10-(2 ’ -pyrrolidonoethyl) 
10-(2’-(N-methyl)-pyrrolidinoethyl) 
10-(2’-piperidinoethyl) 
10-(3’-piperidinopropyl)
10-(3 ’-(N-methyl)-piperazinopropyl) 
10-(2 ’ -morpholinoethy 1)
10-(2’-diethylacetamido)
-5-one1
-5-one2
-5-one3
-5-one4
-5-one5
-5-one6
-5-one7
-5-one8
-5-one9
-5-one10
-5-one11
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FULL PAPERS
